{Reference Type}: Journal Article
{Title}: Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.
{Author}: Latif AL;McQuaker G;Parker A;Clark A;Copland M;
{Journal}: Leuk Res Rep
{Volume}: 2
{Issue}: 2
{Year}: 2013
暂无{DOI}: 10.1016/j.lrr.2013.05.001
{Abstract}: Most patients now receiving a haematopoietic stem cell transplant (HSCT) for chronic myeloid leukaemia (CML) have been treated with first and second line TKIs pre-HSCT, raising concerns that these patients will have more resistant disease and accumulated greater toxicity from sequential lines of therapy, potentially compromising their outcome. We outline a series of 9 patients treated with imatinib then second generation TKIs for CML followed by HSCT and compare their outcomes with patients receiving imatinib-only pre-HSCT. Our case series demonstrates that second line and sequential tyrosine kinase inhibitors followed by HSCT is a safe and effective therapeutic approach for high risk CML.